CKDXFOTCBiological Products, (No Diagnostic Substances)Fiscal year ends June 30Also trades as CYVNY

Opthea Ltd

Financials through fiscal 2025, year ended Jun 30, 2025Last filing: 20-F on Sep 15, 2025

$0.01+0.00 (0.00%)

Close on Oct 19, 2026

Market cap: –
P/E (TTM): –
Dividend yield: –

Opthea Ltd balance sheet

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2025 2025-06-30	FY 2024 2024-06-30	FY 2023 2023-06-30	FY 2022 2022-06-30	FY 2021 2021-06-30	FY 2020 2020-06-30	FY 2019 2019-06-30	FY 2018 2018-06-30
Cash & Equivalents	48	172	89	45	118	43	15	24
Cash & Short-Term Investments	48	172	89	45	118	43	15	24
Receivables	0.42	1.43	0.64	0.26	0.57	0.20	0.21	–
Total Current Assets	57	188	98	60	138	49	26	–
Property, Plant & Equipment	0	0.05	0.03	0.03	0.02	0.03	0.04	–
Operating Lease Right-of-Use Assets	0	0.08	0.17	–	0.09	0.17	–	–
Total Assets	57	189	99	60	138	49	26	–
Accounts Payable	9.74	38	18	11	2.50	4.05	4.18	–
Short-Term Debt	9.74	38	18	11	2.42	4.01	–	–
Current Debt	9.74	38	18	11	2.42	4.01	–	–
Current Portion of Leases	0	0.09	0.10	–	0.11	0.10	–	–
Current Income Taxes Payable	–	0.04	0.05	0.04	0.08	0.04	–	–
Total Current Liabilities	258	64	19	12	3.11	4.76	4.58	–
Long-Term Leases	–	–	0.08	0.08	0	0.08	–	–
Operating Lease Liabilities	0	0.09	0.18	0.08	0.11	0.18	–	–
Deferred Tax Liabilities	0.00	0.00	0.00	0.02	2.34	0.07	–	–
Total Liabilities	258	265	104	12	3.12	4.87	4.59	–
Total Debt	9.74	38	18	11	2.42	4.01	–	–
Common Stock	497	466	321	235	234	114	80	–
Retained Earnings	-742	-580	-359	-217	-124	-79	-68	–
Total Equity	-201	-76	-5.85	48	135	45	22	28

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2025

Profitability, FY2025

Gross margin: –
Operating margin: -623048.0%
Net margin: -651164.0%
Return on equity, FY2025: –

Financial strength

Current ratio: 0.22
Debt to equity: –
Debt to assets: –
Cash to current liabilities: 18.8%

Valuation

P/E ratio: –
Price to sales: –
Price to book: –
Dividend yield: –